Erasca (ERAS) Common Equity (2020 - 2026)
Erasca (ERAS) posted Common Equity of $393.5 million for Q1 2026, up 21.02% on a QoQ basis from $325.2 million in Q4 2025, and down 1.5% year-over-year from $399.5 million in Q1 2025.
Erasca (ERAS) Common Equity (2020 - 2026) Analysis & Trends
Erasca's Common Equity history runs 7 years deep, the most recent figure standing at $393.5 million for Q1 2026.
- Quarterly Common Equity fell 1.5% year-over-year to $393.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.5 million (down 1.5% YoY) and the FY2025 annual result came in at $325.2 million, down 23.22% from the prior year.
- Common Equity was $393.5 million for Q1 2026 at Erasca, up from $325.2 million in the prior quarter.
- Across five years, Common Equity topped out at $451.1 million in Q2 2024 and bottomed at $288.4 million in Q1 2024.
- A 5-year average of $379.6 million and a median of $386.5 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 428.54% — and 2024, when it declined 25.37%.
- Erasca's Common Equity stood at $411.9 million in 2022, then dropped by 23.11% to $316.7 million in 2023, then jumped by 33.73% to $423.5 million in 2024, then declined by 23.22% to $325.2 million in 2025, then climbed by 21.02% to $393.5 million in 2026.
- Business Quant data shows ERAS's Common Equity at $393.5 million in Q1 2026, $325.2 million in Q4 2025, and $347.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 393.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 393.53 Mn |
| Dec 31, 2025 | 325.17 Mn |
| Sep 30, 2025 | 347.89 Mn |
| Jun 30, 2025 | 372.26 Mn |
| Mar 31, 2025 | 399.50 Mn |
| Dec 31, 2024 | 423.50 Mn |
| Sep 30, 2024 | 450.04 Mn |
| Jun 30, 2024 | 451.09 Mn |
| Mar 31, 2024 | 288.41 Mn |
| Dec 31, 2023 | 316.69 Mn |
| Sep 30, 2023 | 338.98 Mn |
| Jun 30, 2023 | 362.71 Mn |
| Mar 31, 2023 | 386.45 Mn |
| Dec 31, 2022 | 411.85 Mn |
| Sep 30, 2022 | 365.32 Mn |
| Jun 30, 2022 | 395.07 Mn |
| Mar 31, 2022 | 424.66 Mn |
| Dec 31, 2021 | 456.53 Mn |
| Sep 30, 2021 | 482.99 Mn |
| Jun 30, 2021 | -150.00 Mn |